scholarly journals Expression of Apogens and Engulfens during Programmed Cell Death in the Nervous System of the Chick Embryo.

1995 ◽  
Vol 58 (2) ◽  
pp. 243-248 ◽  
Author(s):  
Noriko TAKASHITA ◽  
Shunsaku HOMMA ◽  
Rocco J. ROTTELLO ◽  
Pierre-Alan FERNANDEZ ◽  
Junying YUAN ◽  
...  
Keyword(s):  
Cell Death ◽  
Nervous System ◽  
Chick Embryo ◽  
Programmed Cell Death

scholarly journals Regulation of programmed cell death during neural induction in the chick embryo

2011 ◽  
Vol 55 (1) ◽  
pp. 33-43 ◽  
Author(s):  
Anna Gibson ◽  
Neil Robinson ◽  
Andrea Streit ◽  
Guojun Sheng ◽  
Claudio D. Stern
Keyword(s):  
Cell Death ◽  
Chick Embryo ◽  
Programmed Cell Death ◽  
Neural Induction

scholarly journals Anti-programmed cell death-1 (PD-1) monoclonal antibodies involve reversible cranial dura matter

2021 ◽  
Vol 2021 (9) ◽  
Author(s):  
Hiroshi Kataoka ◽  
Daisuke Shimada ◽  
Hitoki Nanaura ◽  
Kazuma Sugie
Keyword(s):  
Central Nervous System ◽  
Cell Death ◽  
Nervous System ◽  
Monoclonal Antibodies ◽  
Programmed Cell Death ◽  
Adverse Effects ◽  
Neuromuscular Disorders ◽  
Neurological Complications ◽  
Programmed Cell Death 1 ◽  
The Central Nervous System

ABSTRACT This case is the first document to describe a patient receiving anti-programmed cell death 1 (PD-1) antibodies which showed cranial dura matter involvement. According to the increasing use of anti-PD-1 monoclonal antibodies, adverse effects can occur in several organs since its ligand PD-L1 and PD-L2 are expressed in a wide variety of tissues. The estimated rate of neurological complications is 1–4.2% of patients, and neuromuscular disorders are the most common. Adverse effects on the central nervous system including encephalitis are less frequent. Here, a patient receiving anti-PD-1 antibodies showed cranial dura matter involvement, and the dura enhancement on MRI was resolved by withdrawal of the treatment with anti-PD-1 antibodies only.

Efficacy of PD-1 or PD-L1 inhibitors and central nervous system metastases in advanced cancer: a meta-analysis

2021 ◽  
Vol 21 ◽  
Author(s):  
Minyong Peng ◽  
Shan Li ◽  
Hui Xiang ◽  
Wen Huang ◽  
Weiling Mao ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Overall Survival ◽  
Cell Death ◽  
Nervous System ◽  
Programmed Cell Death ◽  
Future Research ◽  
Significant Heterogeneity ◽  
Cns Metastases ◽  
Hazard Ratios ◽  
Significant Difference

<P>Background: Little is known about the efficacy of programmed cell death protein-1 (PD-1) or programmed cell death-ligand 1 (PD-L1) inhibitors in patients with central nervous system (CNS) metastases. <P> Objective: Assess the difference in efficacy of PD-1 or PD-L1 inhibitors in patients with and without CNS metastases. <P> Methods: From inception to March 2020, PubMed and Embase were searched for randomized controlled trials (RCTs) about PD-1 or PD-L1 inhibitors. Only trails with available hazard ratios (HRs) for overall survival (OS) of patients with and without CNS metastases simultaneously would be included. Overall survival hazard ratios and their 95% confidence interval (CI) were calculated, and the efficacy difference between these two groups was assessed in the meantime. <P> Results: 4988 patients (559 patients with CNS metastases and 4429 patients without CNS metastases) from 8 RCTs were included. In patients with CNS metastases, the pooled HR was 0.76 (95%CI, 0.62 to 0.93), while in patients without CNS metastases, the pooled HR was 0.74 (95%CI, 0.68 to 0.79). There was no significant difference in efficacy between these two groups (Χ=0.06 P=0.80). <P> Conclusion: With no significant heterogeneity observed between patients with or without CNS metastases, patients with CNS metastases should not be excluded from PD-1 or PD-L1 blockade therapy. Future research should permit more patients with CNS metastases to engage in PD-1 or PD-L1 blockade therapy and explore the safety of PD-1 or PD-L1 inhibitors in patients with CNS metastases.</P>

scholarly journals Programmed cell death 1 expression is associated with inferior survival in patients with primary central nervous system lymphoma

Oncotarget ◽  
2017 ◽  
Vol 8 (50) ◽  
pp. 87317-87328 ◽  
Author(s):  
Hyunsoo Cho ◽  
Se Hoon Kim ◽  
Soo-Jeong Kim ◽  
Jong Hee Chang ◽  
Woo-Ick Yang ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Cell Death ◽  
Nervous System ◽  
Programmed Cell Death ◽  
Central Nervous System Lymphoma ◽  
Programmed Cell Death 1

scholarly journals Clinicopathologic correlates of MYD88 L265P mutation and programmed cell death (PD-1) pathway in primary central nervous system lymphoma

2019 ◽  
Vol 60 (12) ◽  
pp. 2880-2889 ◽  
Author(s):  
Tarsheen K. Sethi ◽  
Alexandra E. Kovach ◽  
Natalie S. Grover ◽  
Li-Ching Huang ◽  
Laura A. Lee ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Cell Death ◽  
Nervous System ◽  
Programmed Cell Death ◽  
Central Nervous System Lymphoma ◽  
Myd88 L265p Mutation ◽  
Myd88 L265p
Sign in / Sign up

Export Citation Format

Share Document